ACE-031 vs Deslorelin
A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
ACE-031
Soluble form of activin type IIB receptor (ActRIIB-Fc fusion protein) that acts as a myostatin and activin trap. Blocks the primary signals that limit muscle growth by sequestering myostatin, activin, and related ligands before they reach cell surface receptors. Phase 2 trials in Duchenne muscular dystrophy demonstrated significant lean mass increases.
Full profileDeslorelin
Potent GnRH super agonist approximately 100× more potent than native GnRH. Used in veterinary medicine for estrus suppression and in human medicine for precocious puberty treatment. In research protocols, used for pituitary desensitization to reset the HPG axis or induce controlled medical suppression of sex hormone production.
Full profile| ACE-031 | Deslorelin | |
|---|---|---|
| Category | Performance & Growth Hormone | Performance & Growth Hormone |
| Also known as | ACVR2B-Fc, ActRIIB-Fc fusion protein | SuvaPryn, Ovuplant, D-His6-Pro9-Et-GnRH |
| Evidence | Investigational (in trials) | Research-stage |
| Dosing range | 0.3mg/kg–3mg/kg mg/kg, every 2–4 weeks (subcutaneous injection) | 50mcg–200mcg mcg, Daily SC for continuous suppression; single or short course for pituitary reset |
| Administration | Subcutaneous injection | Subcutaneous implant (veterinary), Subcutaneous injection |
| Key side effects | Nosebleeds (epistaxis — most common reported AE), Telangiectasia (visible small blood vessel dilation), Gum bleeding, Elevated hemoglobin | Hot flashes, Bone density loss (prolonged suppression), Suppression of testosterone or estrogen, Mood changes, irritability |
| Cited sources | 2 references | 2 references |
Key differences
- Evidence level differs: ACE-031 is investigational (in trials), while Deslorelin is research-stage.
- Administration: ACE-031 — Subcutaneous injection; Deslorelin — Subcutaneous implant (veterinary), Subcutaneous injection.
- Dosing units differ: ACE-031 is dosed in mg/kg, Deslorelin in mcg — they operate at different scales.
- Frequency: ACE-031 is typically every 2–4 weeks (subcutaneous injection); Deslorelin is Daily SC for continuous suppression; single or short course for pituitary reset.
How each works
ACE-031
ACE-031 functions as a decoy receptor, binding myostatin, activin A/B, GDF-11, and BMP-9 in circulation before they can activate cellular ActRIIB receptors. In the Duchenne muscular dystrophy Phase 2 trial, ACE-031 produced meaningful lean body mass increases but was halted due to vascular side effects (epistaxis, telangiectasia) requiring dose and safety optimization.
Deslorelin
Deslorelin produces a robust initial LH/FSH surge (flare effect) followed by profound, sustained pituitary desensitization with continued exposure. This biphasic response is consistent across all high-affinity GnRH super agonists. The flare phase is exploited for reproductive timing in veterinary medicine; the desensitization phase creates the clinical suppression used in precocious puberty and research HPG axis reset protocols.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.